Core Points - BioLineRx Ltd. will release its unaudited financial results for Q3 2024 on November 25, 2024, before U.S. markets open [1] - A conference call will be held at 8:30 a.m. EST featuring remarks by CEO Philip Serlin [2] - The company is focused on developing therapies in oncology and rare diseases, with its first approved product being APHEXDA® for stem cell mobilization in multiple myeloma [4] Company Overview - BioLineRx Ltd. is a commercial stage biopharmaceutical company headquartered in Israel, with operations in the U.S. [4] - The company is advancing a pipeline of investigational medicines targeting sickle cell disease, pancreatic cancer, and other solid tumors [4] - BioLineRx aims to drive innovative therapeutics from development to commercialization, ensuring that discoveries reach patients effectively [4]
BioLineRx to Report Third Quarter 2024 Results on November 25, 2024